Plasma MicroRNA-200c as A Prognostic Biomarker for Epithelial Ovarian Cancer

Addin Trirahmanto, Hariyono Winarto, Aria Kekalih, Ferry Sandra

Abstract


BACKGROUND: Ovarian cancer is the 8th most prevalent cancer in women in the world. Current biomarker prognosis for ovarian cancer has numerous limitations, thus new biomarkers are needed. MicroRNAs (miRs) are considered as potential biomarkers in ovarian cancer as they are stable in blood. One candidate is miR-200c, the main regulator in epithelial transition to the mesenchyme. The aim of this study is to determine the role of miR-200c as prognostic biomarker for epithelial ovarian cancer (EOC).

METHODS: This is a prospective cohort study conducted at Dr. Sardjito Central General Hospital in Yogyakarta from September 2015 to July 2018. Sampling was done using consecutive sampling method. Forty plasma samples of EOC subjects were included in this study. miR-200c expression was quantified using Reverse Transcriptase Quantitative Quantitative Polymerase Chain Reaction (RTqPCR) with miR-16 as the reference gene.

RESULTS: The expression of miR-200c was significantly higher in the group of subjects with preoperative CA-125 levels >500 U/mL (p=0.009) than the group of subjects with preoperative CA-125 levels <500 U/mL. Subjects with higher miR-200c expression had lower survival rate than subjects with lower miR-200c expression, although not statistically significant.

CONCLUSION: The miR-200c could be a promising biomarker for EOC. Further studies with larger sample sizes are needed to clarify the prognostic value of miR200c.

KEYWORDS: miR-200c, epithelial ovarian cancer, prognosis, overall survival


Full Text:

PDF

References


Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424, CrossRef.

Noela F, Nuryanto KH. Epidemiology data of ovarian cancer in Dr. Cipto Mangunkusumo Hospital, Jakarta. Indones J Obstet Gynecol. 2016; 4: 101-6, CrossRef.

Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014; 133: 401-4, CrossRef.

Herzog TJ, Spetzler D, Xiao N, Burnett K, Maney T, Voss A, et al. Impact of molecular profiling on overall survival of patients with advanced ovarian cancer. Oncotarget. 2016; 7: 19840-9, CrossRef.

Taylor PT, Haverstick D. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2005; 97: 151, CrossRef.

Kinose Y, Sawada K, Nakamura K, Kimura T. The Role of microRNAs in ovarian cancer. Biomed Res Int. 2014; 2014: 249393, CrossRef.

Feng X, Wang Z, Fillmore R, Xi Y. MiR-200, a new star miRNA in human cancer. Cancer Lett. 2014; 344: 166-73, CrossRef.

Jiang X, Tang H, Chen T. Epidemiology of gynecologic cancers in China. J Gynecol Oncol. 2018; 29: e7, CrossRef.

Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol. 2016; 34: 2888-98, CrossRef.

Kurman RJ, Shih IEM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016; 186: 733-47, CrossRef.

Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009; 114: 26-31, CrossRef.

Prislei S, Martinelli E, Mariani M, Raspaglio G, Sieber S, Ferrandina G, et al. MiR-200c and HuR in ovarian cancer. BMC Cancer. 2013; 13: 72, CrossRef.

Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008; 14: 2690-5, CrossRef.

Liu W, Zhang K, Wei P, Hu Y, Peng Y, Fang X, et al. Correlation between miR-200 Family Overexpression and Cancer Prognosis. Dis Markers. 2018; 2018: 6071826, CrossRef.




DOI: https://doi.org/10.18585/inabj.v11i3.761

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute